Skip to main content
Premium Trial:

Request an Annual Quote

Neumann Diagnostics Automated Cervical Cancer Test

Neumann Diagnostics has launched its Confidence molecular test portfolio for cervical cancer screening. The test portfolio consists of a human papillomavirus test and an epigenetic biomarker and was evaluated in a multicentre clinical trial involving over 7,000 cervical samples collected from over 6,000 women. In HPV-positive women, aged 25 years or older, the test's sensitivity for severe cervical dysplasia or worse condition at baseline was about 92 percent and its specificity in the same group was about 74 percent. The clinical trial showed that Confidence tests found severe cases up to 12 months earlier than a Pap smear, according to the firm.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.